Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1094-1101

  Inglis, Sally C ^a,b,c   Bebchuk, Judith ^d   Al Suhaim, Sultan A ^a   Case, Jessica ^d   Pfeffer, Marc A ^e   Solomon, Scott D ^e   Hou, Yingxin Rachel ^d   Pitt, Bertram ^f   Dargie, Henry J ^g   Ford, Ian ^h   Kjekshus, John ⁱ   Zannad, Faiez ^j   Dickstein, Kenneth ^k   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^d University of Iowa   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g WESTERN INFIRMARY   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITÉ DE LORRAINE   (France)

^k STAVANGER UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Heart failure; Myocardial infarction; Peripheral vascular disease; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PLACEBO; VALSARTAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; UNIVARIATE ANALYSIS;

ACE; ANGIOTENSIN-CONVERTING-ENZYME; CAPRICORN; CARDIOVASCULAR; CARVEDILOL ON OUTCOME AFTER MYOCARDIAL INFARCTION IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION TRIAL; CV; EPHESUS; EPLERENONE'S NEUROHORMONAL EFFICACY AND SURVIVAL STUDY; HAZARD RATIO; HEART FAILURE; HF; HR; MI; MYOCARDIAL INFARCTION; OPTIMAAL; OPTIMAL TRIAL IN MYOCARDIAL INFARCTION WITH ANGIOTENSIN II ANTAGONIST LOSARTAN; PAD; PERIPHERAL ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; VALIANT; VALSARTAN IN ACUTE MYOCARDIAL INFARCTION TRIAL;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84885318045     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.033     Document Type: Article

References (24)

1. Bertomeu V, Morillas P, Gonzalez-Juanatey JR, et al. Prevalence and prognostic influence of peripheral arterial disease in patients >=40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg 2008;36:189-96.
2. Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction (OPUS-TIMI) 16 study. Am Heart J 2003;145:622-7.
3. Makowsky MJ, McAlister FA, Galbraith PD, et al. Lower extremity peripheral arterial disease in individuals with coronary artery disease: prognostic importance, care gaps, and impact of therapy. Am Heart J 2008;155:348-55.
4. Martinez-Selles M, Barrio J, Hortal J, Ruiz M, Bueno H. Prevalence of peripheral arterial disease and prior stroke in octogenerians with symptomatic severe aortic stenosis or severe coronary artery disease: influence in management and outcome. Int Angiol 2007;26:33-7.
5. Nakata S, Yokoi Y, Matsumoto R, et al. Long-term cardiovascular outcomes following ischaemic heart disease in patients with and without peripheral vascular disease. Osaka City Med J 2008;54:21-30.
6. Dickstein K, Bebchuk J, Wittes J. The high-risk myocardial infarction database initiative. Prog Cardiovasc Dis 2012;54:362-6.
7. Dargie H. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
8. Dargie HJ; The C.A.P.R.I.C.O.R.N. Steering Committee. Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2000;2:325-32.
9. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc Drugs Ther 2001;15:79-87.
10. Pitt B, Remme W, Zannad F, et al. The eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
11. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Am J Cardiol 1999;83:477-81.
12. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
13. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
14. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
15. Bhatt DL, Peterson ED, Harrington RA, et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 2009;30: 1195-202.
16. Chiu JH, Topol EJ, Whitlow PL, et al. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. Am J Cardiol 2003;92: 582-3.
17. Froehlich JB, Mukherjee D, Avezum A, et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006;151:1123-8.
18. Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 2006;48:1567-72.
19. Moussa I, Jaff M, Mehran R, et al. Prevalence and prediction of previously unrecognized peripheral artery disease in patients with coronary artery disease: the peripheral arterial disease in interventional patients study. Catheter Cardiovasc Interv 2009;73:719-24.
20. Bennett PC, Silverman H, Gill P, et al. Peripheral artery disease and Virchow's triad. Thromb Haemost 2009;101:1032-40.
21. Monreal M, Alvarez L, Vilaseca B, et al. Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA). Eur J Intern Med 2008;19:192-7.
22. Hoeks SE, Scholte op Reimer WJM, van Gestel YRBM, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes 2009;2:338-43.
23. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Wahlberg E. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2009;16:39-46.
24. Poredos P, Jug B; for the study group. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007;58: 309-15.